{"id":126841,"date":"2022-04-25T18:50:57","date_gmt":"2022-04-25T18:50:57","guid":{"rendered":"https:\/\/fin2me.com\/?p=126841"},"modified":"2022-04-25T18:50:57","modified_gmt":"2022-04-25T18:50:57","slug":"u-s-fda-approves-gileads-covid-19-drug-for-young-children","status":"publish","type":"post","link":"https:\/\/fin2me.com\/markets\/u-s-fda-approves-gileads-covid-19-drug-for-young-children\/","title":{"rendered":"U.S. FDA approves Gilead's COVID-19 drug for young children"},"content":{"rendered":"
FILE PHOTO: A Gilead Sciences, Inc. logo is seen outside the company headquarters in Foster City, California, U.S. May 1, 2018. REUTERS\/Stephen Lam<\/figcaption>

(Reuters) -The U.S. drug regulator on Monday granted the first full approval for treating COVID-19 in children aged 28 days and older to Gilead Sciences Inc\u2019s drug remdesivir.<\/p>\n

The move comes months after the agency expanded the drug\u2019s emergency use authorization to also include children below 12 years of age weighing at least 3.5 kilograms.<\/p>\n

The Food and Drug Administration\u2019s (FDA) decision makes the drug the first approved COVID-19 treatment for children less than 12 years of age, the agency said.<\/p>\n

The approval is applicable to children who are hospitalized, or have mild-to-moderate disease and are at high risk of severe COVID-19.<\/p>\n

Source: Read Full Article<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"

FILE PHOTO: A Gilead Sciences, Inc. logo is seen outside the company headquarters in Foster City, California, U.S. May 1, 2018. REUTERS\/Stephen Lam(Reuters) -The U.S. […]<\/p>\n","protected":false},"author":3,"featured_media":126840,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[],"yoast_head":"\nU.S. FDA approves Gilead's COVID-19 drug for young children - Fin2me<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/fin2me.com\/markets\/u-s-fda-approves-gileads-covid-19-drug-for-young-children\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"U.S. FDA approves Gilead's COVID-19 drug for young children - Fin2me\" \/>\n<meta property=\"og:description\" content=\"FILE PHOTO: A Gilead Sciences, Inc. logo is seen outside the company headquarters in Foster City, California, U.S. May 1, 2018. REUTERS\/Stephen Lam(Reuters) -The U.S. [...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/fin2me.com\/markets\/u-s-fda-approves-gileads-covid-19-drug-for-young-children\/\" \/>\n<meta property=\"og:site_name\" content=\"Fin2me\" \/>\n<meta property=\"article:published_time\" content=\"2022-04-25T18:50:57+00:00\" \/>\n<meta name=\"author\" content=\"Mark\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:image\" content=\"https:\/\/fin2me.com\/wp-content\/uploads\/2022\/04\/U.S.-FDA-approves-Gileads-COVID-19-drug-for-young-children.jpg\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Mark\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/fin2me.com\/markets\/u-s-fda-approves-gileads-covid-19-drug-for-young-children\/\",\"url\":\"https:\/\/fin2me.com\/markets\/u-s-fda-approves-gileads-covid-19-drug-for-young-children\/\",\"name\":\"U.S. FDA approves Gilead's COVID-19 drug for young children - Fin2me\",\"isPartOf\":{\"@id\":\"https:\/\/fin2me.com\/#website\"},\"datePublished\":\"2022-04-25T18:50:57+00:00\",\"dateModified\":\"2022-04-25T18:50:57+00:00\",\"author\":{\"@id\":\"https:\/\/fin2me.com\/#\/schema\/person\/ad0e9920e03d3b41c7ad02a18375d76a\"},\"breadcrumb\":{\"@id\":\"https:\/\/fin2me.com\/markets\/u-s-fda-approves-gileads-covid-19-drug-for-young-children\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/fin2me.com\/markets\/u-s-fda-approves-gileads-covid-19-drug-for-young-children\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/fin2me.com\/markets\/u-s-fda-approves-gileads-covid-19-drug-for-young-children\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/fin2me.com\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Markets\",\"item\":\"https:\/\/fin2me.com\/category\/markets\/\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"U.S. FDA approves Gilead's COVID-19 drug for young children\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/fin2me.com\/#website\",\"url\":\"https:\/\/fin2me.com\/\",\"name\":\"Fin2me\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/fin2me.com\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\/\/fin2me.com\/#\/schema\/person\/ad0e9920e03d3b41c7ad02a18375d76a\",\"name\":\"Mark\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/fin2me.com\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/39b72719fb75a2d3c7d7695026648602?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/39b72719fb75a2d3c7d7695026648602?s=96&d=mm&r=g\",\"caption\":\"Mark\"}}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"U.S. FDA approves Gilead's COVID-19 drug for young children - Fin2me","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/fin2me.com\/markets\/u-s-fda-approves-gileads-covid-19-drug-for-young-children\/","og_locale":"en_US","og_type":"article","og_title":"U.S. FDA approves Gilead's COVID-19 drug for young children - Fin2me","og_description":"FILE PHOTO: A Gilead Sciences, Inc. logo is seen outside the company headquarters in Foster City, California, U.S. May 1, 2018. REUTERS\/Stephen Lam(Reuters) -The U.S. [...]","og_url":"https:\/\/fin2me.com\/markets\/u-s-fda-approves-gileads-covid-19-drug-for-young-children\/","og_site_name":"Fin2me","article_published_time":"2022-04-25T18:50:57+00:00","author":"Mark","twitter_card":"summary_large_image","twitter_image":"https:\/\/fin2me.com\/wp-content\/uploads\/2022\/04\/U.S.-FDA-approves-Gileads-COVID-19-drug-for-young-children.jpg","twitter_misc":{"Written by":"Mark","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/fin2me.com\/markets\/u-s-fda-approves-gileads-covid-19-drug-for-young-children\/","url":"https:\/\/fin2me.com\/markets\/u-s-fda-approves-gileads-covid-19-drug-for-young-children\/","name":"U.S. FDA approves Gilead's COVID-19 drug for young children - Fin2me","isPartOf":{"@id":"https:\/\/fin2me.com\/#website"},"datePublished":"2022-04-25T18:50:57+00:00","dateModified":"2022-04-25T18:50:57+00:00","author":{"@id":"https:\/\/fin2me.com\/#\/schema\/person\/ad0e9920e03d3b41c7ad02a18375d76a"},"breadcrumb":{"@id":"https:\/\/fin2me.com\/markets\/u-s-fda-approves-gileads-covid-19-drug-for-young-children\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/fin2me.com\/markets\/u-s-fda-approves-gileads-covid-19-drug-for-young-children\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/fin2me.com\/markets\/u-s-fda-approves-gileads-covid-19-drug-for-young-children\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/fin2me.com\/"},{"@type":"ListItem","position":2,"name":"Markets","item":"https:\/\/fin2me.com\/category\/markets\/"},{"@type":"ListItem","position":3,"name":"U.S. FDA approves Gilead's COVID-19 drug for young children"}]},{"@type":"WebSite","@id":"https:\/\/fin2me.com\/#website","url":"https:\/\/fin2me.com\/","name":"Fin2me","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/fin2me.com\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/fin2me.com\/#\/schema\/person\/ad0e9920e03d3b41c7ad02a18375d76a","name":"Mark","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/fin2me.com\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/39b72719fb75a2d3c7d7695026648602?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/39b72719fb75a2d3c7d7695026648602?s=96&d=mm&r=g","caption":"Mark"}}]}},"_links":{"self":[{"href":"https:\/\/fin2me.com\/wp-json\/wp\/v2\/posts\/126841"}],"collection":[{"href":"https:\/\/fin2me.com\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/fin2me.com\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/fin2me.com\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/fin2me.com\/wp-json\/wp\/v2\/comments?post=126841"}],"version-history":[{"count":0,"href":"https:\/\/fin2me.com\/wp-json\/wp\/v2\/posts\/126841\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/fin2me.com\/wp-json\/wp\/v2\/media\/126840"}],"wp:attachment":[{"href":"https:\/\/fin2me.com\/wp-json\/wp\/v2\/media?parent=126841"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/fin2me.com\/wp-json\/wp\/v2\/categories?post=126841"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/fin2me.com\/wp-json\/wp\/v2\/tags?post=126841"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}